Nuclear Medicine and Brain Imaging

An optimized protocol of this book aims to study and accumulate newly radiotracers that were used for brain imaging in the nuclear medicine field like [99mTc]histamine, [99mTc] ropinirole , [99mTc] (Sn) oxiracetam, [99mTc] bioquin HMPAO [ 99mTc]BH , [99mTc ](Na2S2O4) oxiracetam, [99mTc] N (BDTC)2 , [99mTc]N (PDTC)2 , [99mTc] N (EOEDTC)2, [99mTc] N-piracetam , [99mTc] N-histamine , [99mTc] (CO)3 DEDT , [99mTc] (CO)3-5HTIDA , [99mTc] (CO)3-OH-PP-CS2, [99mTc] (CO)3 oxiracetam , [125I] sibutramine,[125I] iodofluoxetine , [99mTc] phenobarbital , [125I] trazodone , and [125I] haloperidol. That was labeled with [125I] or [99mTc]. Factors such as the amount of oxidizing and reducing agent, amount of substrate, pH, reaction temperature and reaction time, have been systematically studied to optimize the labeling process. The labeled compound was separated and purified using thin layer chromatography (TLC), paper electrophoreses and high performance liquid chromatography (HPLC). Biodistribution studies indicated that the [99mTc]piracetam complex has a high brain uptake of 13.5 ± 0.12 % ID/organ at 5 min post injection. That considered better than recently discovered agents.